Avalyn Pharma's IPO aims to fund inhaled IPF therapies as AP01 shows positive Phase II results. Read the full analysis here.
NTU Singapore is working with China's Southern University of Science and Technology (SUSTech) and Swedish biotechnology ...
A new inhaled therapy targeting lung inflammation shows promise in reducing damage and improving recovery after severe ...
A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers ...
University of Colorado Denver Biomedical Engineering Associate Professor Chelsea Magin is developing a lung model to help ...
A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers ...
Nanyang Technological University, Singapore (NTU Singapore) is working with China's Southern University of Science and Technology (SUSTech) and Swedish biotechnology company Lipigon Pharmaceuticals AB ...
A new inhaled therapy targets ANGPTL4 to reduce lung inflammation, fluid buildup, and scarring after infections. Preclinical ...
Researchers at National Jewish Health and collaborating institutions have uncovered a critical mechanism driving persistent ...
Her treatment is complicated by high costs and insurance limits, affecting consistent access to care, medication, and ...
Backed by Novo Holdings and multiple other prominent investors, the biotech is developing what it’s positioning as superior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results